Diffuse Bone Marrow Involvement of Multiple Myeloma on [ 18 F]PSMA-1007 PET/CT : Is There a Theranostic Potential?

Clin Nucl Med. 2022 Nov 1;47(11):968-969. doi: 10.1097/RLU.0000000000004286. Epub 2022 May 27.

Abstract

A 71-year-old man presented with chronic anemia (hemoglobin 7.3 g/dL). Further serum analyses showed elevated prostate-specific antigen (13 ng/mL), suggestive of prostate cancer. However, ultrasound-guided transrectal sextant biopsy did not find any evidence of prostate cancer. In order to improve guidance of intended repeated biopsy, [ 18 F]prostate-specific membrane antigen (PSMA) 1007 PET/CT was performed, which showed a solitary lesion with strong PSMA expression in the left peripheral zone in the prostate gland. Surprisingly, also a diffuse bone marrow involvement with predominantly osteolytic lesions was observed. This massive osseous tumor burden was clearly discordant to the only relatively mild elevated prostate-specific antigen. The subsequent bone biopsy revealed multiple myeloma. This case does not only highlight a possible pitfall on PSMA PET/CT, but also raises the question on how far PSMA ligands may offer diagnostic and therapeutic potential in multiple myeloma.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Bone Marrow / pathology
  • Gallium Radioisotopes
  • Humans
  • Male
  • Multiple Myeloma* / diagnostic imaging
  • Niacinamide / analogs & derivatives
  • Oligopeptides
  • Positron Emission Tomography Computed Tomography
  • Precision Medicine
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / pathology

Substances

  • Gallium Radioisotopes
  • Oligopeptides
  • PSMA-1007
  • Niacinamide
  • Prostate-Specific Antigen